Bicara Therapeutics BCAX 深 滬
等待開盤 09-16 09:30:00 美东时间
11.47
-0.150
-1.29%
華盛通- 最 高11.785
- 今 開11.70
- 成交量 14.55万股
- 最 低 11.33
- 昨 收 11.62
- 總市值 6.26亿
- 52周最高 28.09
- 市盈率 靜 --
- 換手率 0.27%
- 52周最低 7.80
- 委 比 -26.67%
- 總股本 5453.62万
- 歷史最高 28.09
- 量 比 0.68
- 振 幅 3.92%
- 歷史最低 7.80
- 每 手 1
- 風險率 4.84%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Bicara Therapeutics to Participate in Upcoming Investor Conferences
Boston, Aug. 27, 2025 – Bicara Therapeutics Inc. announced that its management will participate in three upcoming investor conferences in September 2025. The meetings include the Cantor Global Healthcare Conference, the Wells Fargo Healthcare Conference, and the Morgan Stanley Global Healthcare Conference. Live webcasts and replays will be available on the company's Investor Relations website. Bicara is focused on developing bifunctional therapi...
08-27 20:01
Piper Sandler initiates coverage of oncology companies
Piper Sandler launched coverage for a few biotech companies in the oncology space, as mentioned below: CG Oncology (NASDAQ:CGON) rated Overweight with a $55 price target: "Investor expectations for cr...
08-19 23:17
Piper Sandler Initiates Coverage On Bicara Therapeutics with Overweight Rating, Announces Price Target of $36
Piper Sandler analyst Kelsey Goodwin initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Overweight rating and announces Price Target of $36.
08-19 19:48
Bicara Therapeutics Q2 EPS $(0.50) Beats $(0.54) Estimate
Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.54) by 7.41 percent. This is a 97.37 percent increase over losses of $(19.01) per share
08-12 19:33
Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Bicara Therapeutics reported financial results and updates on its lead drug, ficerafusp alfa, for Q2 2025. The company has $437 million in cash, expected to fund operations into 2029. Updated Phase 1/1b data showed strong responses in HPV-negative recurrent/metastatic HNSCC patients, with a 54% objective response rate and 46% 2-year OS rate. Additional Phase 1b expansion cohorts are ongoing, with data expected in Q1 2026. R&D expenses rose due to...
08-12 11:30
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Bicara Therapeutics Inc. announced that its management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025. The presentation will be available via webcast on Bicara’s Investor Relations website, with a replay archived post-event. Bicara focuses on developing bifunctional therapies for solid tumors, with its lead program, ficerafusp alfa, targeting EGFR and TGF-β to reverse tumor micro...
06-03 20:01
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
Bicara Therapeutics presented updated Phase 1/1b trial data on ficerafusp alfa in combination with pembrolizumab for first-line recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). In HPV-negative patients with PD-L1 CPS ≥1, the therapy demonstrated deep and durable responses, including an 80% deep response rate (≥80% tumor shrinkage), median duration of response of 21.7 months, median overall survival (OS) of 21.3 months, and a 46...
06-01 17:12
核心药物试验数据亮眼 大摩维持Bicara Therapeutics(BCAX.US)“买入”评级
摩根士丹利分析师Judah Frommer在Bicara Therapeutics公布Ficerafusp alfa的1/1b期临床试验中期数据后，维持对该股的“买入”评级，目标价保持在36美元。
05-28 14:10
美股大行评级 | 潜在涨幅112.77%！Craig-Hallum上调PLAYSTUDIOS目标价至3美元，评级升至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1132955525493317632.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Craig-Hallum：上调PLAYSTUDIOS(MYPS)评级至"买入"，目标价从2美元升至3美元</p> <p>• Leerink Partners：上调Fulcrum Therapeutics(FULC)评级至"
05-24 08:40
Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On?
Bicara Therapeutics Inc. (NASDAQ: BCAX) shares are trading lower Friday following the release of updated interim data.
05-24 04:46
